Select Page

Press

  • Our Prediction for 2017: Out with Post Hoc and Go DeFT! 

    Our Prediction for 2017: Out with Post Hoc and Go DeFT! 

    Posted on February 10, 2017 by Katie Porter
    It’s a new year and welcome to it! Pundits are making a lot of predictions about the decline of science and technology under the new administration in Washington DC, and I’m here with a contrarian view. We bet on biotechnology! We predict that the next four years will see a revolution and acceleration of innovation, regardless of ...
    Read more
  • Will EpiVax Tools be the Ancer to Cancer?

    Will EpiVax Tools be the Ancer to Cancer?

    Posted on January 2, 2017 by Annie De Groot
    EpiVax Oncology – New Year, New Endeavor! A nice story in ConvergenceRI that describes the rapid growth of EpiVax and our decision to invest in a new spin-out company in 2017: Welcome EpiVax Oncology! Annie was interviewed by Richard Asinof about “EpiVax Oncology” in the Epibar: link to the full story here, and read more about the ...
    Read more
  • $1.87M BioDefense Grant to EpiVax and CUBRC

    $1.87M BioDefense Grant to EpiVax and CUBRC

    Posted on December 19, 2016 by Annie De Groot
    CUBRC and EpiVax Awarded DTRA Grant worth $1.87 Million to Perform Research into Vaccine Antigen Design for Burkholderia pseudomallei Buffalo, NY – December 19, 2017 – CUBRC, Inc.’s President and CEO, Tom McMahon, announced today that CUBRC’s Biological and Medical Sciences team, in collaboration with EpiVax, Inc., has received a four-year grant worth $1.87 million from ...
    Read more
  • The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

    The Ancer to Cancer: A computational pipeline for personalized cancer vaccine design

    Posted on December 11, 2016 by Annie De Groot
    Building on 18 years of commercially successful research and development in the field of computational immunology, EpiVax has now developed Ancer™, a personalized cancer vaccine platform. Ancer is a high-speed, secure, cloud-based commercial platform for processing cancer/normal protein sets, identifying high-quality patient-specific neo-antigens, and designing personalized cancer vaccines. EpiVax has established a reputation for innovative cloud-based ...
    Read more
  • Bio-Europe Spring

    Bio-Europe Spring

    Posted on December 8, 2016 by Katie Porter
    EpiVax will be joining more than 1,400 companies from over 45 countries at Bio-Europe Spring, the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe’s most innovative biopharma clusters. Partner with us to hear about our new immunoinformatics platform accelerating the advancement of personalized cancer vaccine design. Partnering is ...
    Read more
  • EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding

    EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding

    Posted on September 12, 2016 by Annie De Groot
    September 6, 2016 (Providence, RI) – EpiVax, Inc., “immune engineering” pioneer, has won a new $600,000 National Institutes of Health grant under the Small Business Innovation Research (SBIR) program to improve a vaccine for the problematic H7N9 avian influenza virus. The vaccine development program will be directed by Annie De Groot, M.D., EpiVax CEO/CSO, and Lenny Moise, Ph.D., EpiVax ...
    Read more
  • Immunogenicity and Tolerance Seminar (updated)

    Immunogenicity and Tolerance Seminar (updated)

    Posted on April 28, 2016 by Annie De Groot
    Platine and EpiVax are co-organizing their 2nd seminar on Immunogenicity and Tolerance on October 24th, 2016. The conference agenda is shown below. Click this link to register This meeting will focus on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, ...
    Read more
  • Biotech CEO of the Year

    Biotech CEO of the Year

    Posted on March 30, 2016 by Annie De Groot
    Standards of excellence. Models of advocacy. An unparalleled ability to succeed. These are characteristics of the vaccine industry’s top achievers. Last night at the 9th Vaccine Industry Excellence (ViE) Awards, winners were recognized for their outstanding contributions to the vaccine industry over the past 12-months. EpiVax’s own Annie De Groot took home Biotech CEO of the Year, and she is in good company – Sanofi ...
    Read more
  • AAPS Biotechnology Conference May 2016

    AAPS Biotechnology Conference May 2016

    Posted on February 29, 2016 by Annie De Groot
    https://www.aaps.org/nationalbiotech/
    Read more
  • BioEurope Spring 2016

    BioEurope Spring 2016

    Posted on February 29, 2016 by Annie De Groot
    We’re off to Stockholm for BIO-Europe Spring (BES2016), which will take place 4–6 April in Stockholm, Sweden. We will be joining international leaders from biotech, pharma and finance to identify and enter new strategic relationships. Sign up to meet us now through the partnering system or via email
    Read more
  • EpiVax at Bio Asia 2016

    EpiVax at Bio Asia 2016

    Posted on February 29, 2016 by Annie De Groot
    Lucky us! the 13th International Bio Asia Conference is scheduled for March 15-16, 2016 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...
    Read more
  • We rush to conquer Zika, but . . . how?

    We rush to conquer Zika, but . . . how?

    Posted on February 14, 2016 by Annie De Groot
    As a Valentine’s day gift to women at risk of Zika everywhere, we’re providing access to our initial analysis of Zika and our opinion on Zika vaccine design.  If you just want access to the slides, here they are: https://bit.ly/Zika_Slides_EpiVax_2016 What’s the key point of this post? We think that it’s won’t be so easy to make an effective Zika vaccine. Rushing ...
    Read more
  • Zika envelope is a 'stealth protein'

    Zika envelope is a 'stealth protein'

    Posted on February 6, 2016 by Annie De Groot
    The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...
    Read more
  • Zika envelope is a 'stealth protein'

    Zika envelope is a ‘stealth protein’

    Posted on February 6, 2016 by Annie De Groot
    The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...
    Read more
  • Step into the 21st Century, Novartis!

    Step into the 21st Century, Novartis!

    Posted on February 1, 2016 by Annie De Groot
    (This post has been corrected, thanks Sebastian!) I love “Google Alerts”. They let me know when someone has just published an article citing one of our articles, and link me to new, exciting work that has just been made available on the web. Last week, my google alert linked me to a new paper by Sebastian Spindeldreher’s ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here